Fifteen Years of Annual Mass Treatment of Onchocerciasis with Ivermectin Have Not Interrupted Transmission in the West Region of Cameroon
Table 2
Comparing mf prevalence among adults at baseline (1996) and followup in 2005, 2006, and 2011, three months, six months, and eleven months, respectively, after mass treatment, in West Region, Cameroon.
District
Community
Baseline, 1996 ()
Followup, 2005 ()
Followup, 2006 ()
Followup, 2011 ()
No. examined
No. positive
% mf positive
No. examined
No. positive
% mf positive
No. examined
No. positive
% mf positive
No. examined
No. positive
% mf positive
Bakassa
61
36
59.0
140
2
1.4*
97
2
2.1
251
14
5.6
Bafang
Bakonti
52
36
69.2
99
3
3.0*
75
3
4.0
338
12
3.6
Fondjanti
124
87
70.2
125
8
6.4
Bakambe
122
65
53.3
105
3
2.9*
91
6
6.6
ND
ND
ND
Baham
Bapi
145
77
53.1
ND
ND
ND
ND
ND
ND
189
21
11.1
Bandja
Babouantou (Batoula)
68
49
72.1
53
7
13.2*
76
14
18.4
84
18
21.4
Bangangté
Batchingou
84
61
72.6
102
11
10.8*
80
14
17.5
247
45
18.2
Ndjipta III (Fop-Tchui)
88
71
80.7
78
1
1.3*
57
6
10.5**
92
9
9.8
Foumbot
Fossang-chefferie*
32
28
87.5
71
13
18.3*
72
19
26.4**
150
19
12.7***
Njone
59
52
88.1
135
11
8.1*
122
41
33.6**
167
70
41.9***
Kekem
Mbafam
39
27
69.2
95
2
2.1*
112
4
3.6
163
8
4.9
Penka-Michel
Bakassa
57
32
56.1
ND
ND
ND
ND
ND
ND
195
7
3.6
Foumban
Folap
ND
ND
ND
ND
ND
ND
ND
ND
ND
265
0
0.0
Kouoptamo
Njisseng
ND
ND
ND
ND
ND
ND
ND
ND
ND
168
5
3.0
Malantouen
Matoupou
ND
ND
ND
ND
ND
ND
ND
ND
ND
170
13
7.6
Massangam
Makouopsap
ND
ND
ND
ND
ND
ND
ND
ND
ND
99
59
59.6
931
621
66.7
878
53
6.0
*
782
109
13.9
2703
308
11.4
ND: not done.
*Significant ( < 0.05)—followup 2005 compared with the baseline.
**Significant ( < 0.05)—followup 2006 compared with 2005 followup.
***Significant ( < 0.05)—followup 2011 compared with 2006 followup.
